Astellas Pharma declined to exercise its option on AviadoBio's gene therapy treatment for frontotemporal dementia, the UK biotech company announced Tuesday. The decision reflects broader challenges facing the gene therapy sector as pharmaceutical companies become more selective with their investments.
Frontotemporal dementia represents a significant unmet medical need, affecting patients' behavior, language, and movement. Gene therapy approaches have shown promise in treating various neurological conditions, though the field has faced setbacks in recent years with safety concerns and mixed clinical results.